Guidance published on permanent implant brachytherapy devices to treat pancreatic cancer

We have  published new guidance on the use of permanent implant brachytherapy devices (PIBD) to treat pancreatic cancer when surgery is not an option (unresectable pancreatic cancer).
According to the guidance the use of PIBD to treat unresectable pancreatic cancer in addition to conventional treatment is not supported by the evidence.

It states that randomised control trials on the use of brachytherapy did not show any improvement for people living with unresectable pancreatic cancer, compared to using chemotherapy alone.

In addition, according to the guidance, treatment with brachytherapy is technically challenging with a risk of adverse events. To read the guidance in full click here